<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Feldman, Ted</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Controversies in Structural Heart Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">34-35</style></pages><abstract><style  face="normal" font="default" size="100%">The fastest growing area of interventional cardiology is structural interventions, especially for aortic valve stenosis (transcatheter aortic valve replacement) and mitral regurgitation (mitral clipping) [Meier P, Timmis A. Heart 2012]. In total, the number of valve procedures has increased over 30% from a total of 149,407 in 2006 to 194,254 in 2010 [Stuge O, Liddicoat J. J Thorac Cardiovasc Surg 2006]. This article discusses the present status and future direction of interventional mitral valve therapies.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>